Latest News
Conference Coverage
Flotetuzumab for AML passes phase 1 test
Flotetuzumab, a novel bispecific monoclonal antibody that employs a proprietary technology to redirect T lymphocytes to kill CD123-expressing...
Conference Coverage
CRP may predict survival after immunotherapy for lung cancer
Median overall survival was more than three times longer for patients with CRP levels at or below 50 mg/L than for those with levels above 50 mg/L...
News
FDA grants accelerated approval to copanlisib for relapsed follicular lymphoma
The Food and Drug Administration has granted accelerated approval to copanlisib (Aliqopa) for the treatment of adults with relapsed follicular...
Conference Coverage
Tocilizumab looks promising for corticosteroid refractory anti-PD-1-related adverse events
CHICAGO – In a review of patients treated with nivolumab, 27 of 34 who were refractory to corticosteroids and treated with tocilizumab for high-...
Conference Coverage
New antibodies, drugs for refractory and relapsed myeloma are effective in patients over 65
MADRID – Patients with refractory/relapsed multiple myeloma had similar rates of progression-free survival whether they were younger than age 65...
Feature
CMS alerts physicians of payment reductions for PQRS noncompliance
Some doctors will see their payments reduced by 2%.
Conference Coverage
VIDEO: Educational intervention boosts A fib anticoagulation
BARCELONA – Patient education and feedback increased anticoagulation and cut strokes.
News from the FDA/CDC
E-cigarettes most popular among youngest adults
CDC estimates that over 15% of U.S. adults have at least tried vaping.
Conference Coverage
MONARCH 3: Abemaciclib plus AI boosts PFS in HR+/HER2- breast cancer
MADRID – The study was stopped for efficacy at the interim analysis and median PFS for abemaciclib plus letrozole or anastrozole has not yet been...
Conference Coverage
Calcitonin-to-CEA ratio predicts medullary thyroid cancer survival
Can a ratio of serum calcitonin to carcinoembryonic antigen predict survival in patients with medullary thyroid cancer?
Conference Coverage
AML risk is doubled in low-risk thyroid cancer patients unnecessarily given radioactive iodine therapy
MADRID - Unnecessary radioactive iodine treatment is associated with nearly twice the risk of developing acute myeloid leukemia (AML) in patients...